Clinical Trials · NCT02689921
NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer
- Phase
- Phase 2
- Recruitment status
- Unknown
- Sponsor
- Midwestern Regional Medical Center
- Enrollment
- 7
- Start date
- Apr 2016
- Locations
- 2 sites, United States
- Primary endpoint
- Evidence of Pathological Response